Literature DB >> 28978302

Publisher Correction: Indole 3-acetic acid, indoxyl sulfate and paracresyl-sulfate do not influence anemia parameters in hemodialysis patients.

.   

Abstract

Entities:  

Year:  2017        PMID: 28978302      PMCID: PMC5627453          DOI: 10.1186/s12882-017-0716-1

Source DB:  PubMed          Journal:  BMC Nephrol        ISSN: 1471-2369            Impact factor:   2.388


× No keyword cloud information.

Erratum

In the original publication of this article [1], Table 3 is incorrect, several cell values in column 4 (no ESA (n = 8)) have been incorrectly shifted during typesetting. In this Erratum the correct and incorrect version of Table 3 are published. The publisher apologizes for the inconvenience caused by this error to the authors and readers. Incorrect version of Table 3 as published on 26 July 2017. The incorrect cells are displayed in italics Correct version of Table 3, the corrected cells are displayed in bold
Table 1

Incorrect version of Table 3 as published on 26 July 2017. The incorrect cells are displayed in italics

Hb >10 g/dLHb ≤10 g/dL p-value
no ESA (n = 63)ESA ≤40 μg/w (n = 75)ESA >40 μg/w (n = 41)no ESA (n = 8)ESA ≤40 μg/w (n = 25)ESA >40 μg/w (n = 28)
Age (years)67.8 ± 15.367.1 ± 16.269.9 ± 15.474.5 ± 8.164.8 ± 17.665.9 ± 18.30.63
Gender (male)61.9%58.7%41.5%62.5%64.0%42.9%0.19
Diabetes44.4%41.3%43.9%37.5%48.0%35.7%0.96
Hemoglobin (g/dL)11.6 ± 0.911.2 ± 0.811.1 ± 0.89.6 ± 0.69.5 ± 0.49.0 ± 0.9<0.001
TSAT (%)29.2 ± 13.523.5 ± 9.222.7 ± 11.145.8 ± 27.425.6 ± 9.820.1 ± 17.4<0.001
Ferritin (ng/mL)480 ± 330426 ± 285473 ± 304 1341 ± 1541 636 ± 314677 ± 901<0.001
Albumin (g/L)38.4 ± 4.439.2 ± 4.137.5 ± 4.837.8 ± 4.633.0 ± 7.8<0.001
β2 microglobulin (mg/L)26.2 ± 7.025.7 ± 6.927.4 ± 8.2 34.1 ± 6.4 25.6 ± 6.227.4 ± 7.00.008
Parathormone (pg/mL)268 ± 318284 ± 315195 ± 207 35.8 ± 9.8 264 ± 354237 ± 4380.83
Predialysis creatinine (μmol/L)764 ± 282769 ± 242684 ± 250 224 ± 299 757 ± 220638 ± 2390.08
Predialysis urea (mmol/L)20.8 ± 5.921.7 ± 6.720.0 ± 6.5 623 ± 153 21.0 ± 6.119.6 ± 8.30.39
C-reactive protein (mg/L)12.2 ± 18.912.7 ± 28.426.0 ± 67.4 17.2 ± 5.5 23.1 ± 49.936.5 ± 37.10.02
IAA (μmol/L)5.10 ± 5.285.73 ± 5.973.51 ± 3.50 51.9 ± 97.3 4.67 ± 3.053.78 ± 2.600.09
IS (μmol/L)92.8 ± 54.797.9 ± 45.2100.9 ± 49.9 2.29 ± 1.30 85.2 ± 55.582.3 ± 61.90.54
PCS(μmol/L)169 ± 101172 ± 94150 ± 97 78.1 ± 37.6 175 ± 9896 ± 990.01
Iron medication
 IV iron medication54.0%68.0%73.2% 135 ± 75 48.0%64.3%0.10
 Iron dose (mg/mo)175 ± 188228 ± 245351 ± 318163 ± 292124 ± 167314 ± 3740.002
HDF (%)54.0%30.7%31.7%50.0%52.0%46.4%0.05
Kt/V1.51 ± 0.261.50 ± 0.281.50 ± 0.421.46 ± 0.301.57 ± 0.261.51 ± 0.340.95
Table 2

Correct version of Table 3, the corrected cells are displayed in bold

Hb >10 g/dLHb ≤10 g/dL p-value
no ESA (n = 63)ESA ≤40 μg/w (n = 75)ESA >40 μg/w (n = 41)no ESA (n = 8)ESA ≤40 μg/w (n = 25)ESA >40 μg/w (n = 28)
Age (years)67.8 ± 15.367.1 ± 16.269.9 ± 15.474.5 ± 8.164.8 ± 17.665.9 ± 18.30.63
Gender (male)61.9%58.7%41.5%62.5%64.0%42.9%0.19
Diabetes44.4%41.3%43.9%37.5%48.0%35.7%0.96
Hemoglobin (g/dL)11.6 ± 0.911.2 ± 0.811.1 ± 0.89.6 ± 0.69.5 ± 0.49.0 ± 0.9<0.001
TSAT (%)29.2 ± 13.523.5 ± 9.222.7 ± 11.145.8 ± 27.425.6 ± 9.820.1 ± 17.4<0.001
Ferritin (ng/mL)480 ± 330426 ± 285473 ± 304 1341 ± 1541 636 ± 314677 ± 901<0.001
Albumin (g/L)38.4 ± 4.439.2 ± 4.137.5 ± 4.8 34.1 ± 6.4 37.8 ± 4.633.0 ± 7.8<0.001
β2 microglobulin (mg/L)26.2 ± 7.025.7 ± 6.927.4 ± 8.2 35.8 ± 9.8 25.6 ± 6.227.4 ± 7.00.008
Parathormone (pg/mL)268 ± 318284 ± 315195 ± 207 224 ± 299 264 ± 354237 ± 4380.83
Predialysis creatinine (μmol/L)764 ± 282769 ± 242684 ± 250 623 ± 153 757 ± 220638 ± 2390.08
Predialysis urea (mmol/L)20.8 ± 5.921.7 ± 6.720.0 ± 6.5 17.2 ± 5.5 21.0 ± 6.119.6 ± 8.30.39
C-reactive protein (mg/L)12.2 ± 18.912.7 ± 28.426.0 ± 67.4 51.9 ± 97.3 23.1 ± 49.936.5 ± 37.10.02
IAA (μmol/L)5.10 ± 5.285.73 ± 5.973.51 ± 3.50 2.29 ± 1.30 4.67 ± 3.053.78 ± 2.600.09
IS (μmol/L)92.8 ± 54.797.9 ± 45.2100.9 ± 49.9 78.1 ± 37.6 85.2 ± 55.582.3 ± 61.90.54
PCS(μmol/L)169 ± 101172 ± 94150 ± 97 135 ± 75 175 ± 9896 ± 990.01
Iron medication
 IV iron medication54.0%68.0%73.2% 37.5% 48.0%64.3%0.10
 Iron dose (mg/mo)175 ± 188228 ± 245351 ± 318163 ± 292124 ± 167314 ± 3740.002
HDF (%)54.0%30.7%31.7%50.0%52.0%46.4%0.05
Kt/V1.51 ± 0.261.50 ± 0.281.50 ± 0.421.46 ± 0.301.57 ± 0.261.51 ± 0.340.95
  1 in total

1.  Indole 3-acetic acid, indoxyl sulfate and paracresyl-sulfate do not influence anemia parameters in hemodialysis patients.

Authors:  Stanislas Bataille; Marion Pelletier; Marion Sallée; Yvon Berland; Nathalie McKay; Ariane Duval; Stéphanie Gentile; Yosra Mouelhi; Philippe Brunet; Stéphane Burtey
Journal:  BMC Nephrol       Date:  2017-07-26       Impact factor: 2.388

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.